305 related articles for article (PubMed ID: 15126252)
1. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
3. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
5. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
[TBL] [Abstract][Full Text] [Related]
9. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients. The cost-effectiveness of screening for type 2 diabetes.
Ann Intern Med; 2004 May; 140(9):I29. PubMed ID: 15126270
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
13. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.
Hu D; Hook EW; Goldie SJ
Ann Intern Med; 2004 Oct; 141(7):501-13. PubMed ID: 15466767
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of digital mammography breast cancer screening.
Tosteson AN; Stout NK; Fryback DG; Acharyya S; Herman BA; Hannah LG; Pisano ED;
Ann Intern Med; 2008 Jan; 148(1):1-10. PubMed ID: 18166758
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
[TBL] [Abstract][Full Text] [Related]
18. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
19. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
Kahn R; Alperin P; Eddy D; Borch-Johnsen K; Buse J; Feigelman J; Gregg E; Holman RR; Kirkman MS; Stern M; Tuomilehto J; Wareham NJ
Lancet; 2010 Apr; 375(9723):1365-74. PubMed ID: 20356621
[TBL] [Abstract][Full Text] [Related]
20. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
Laxy M; Wilson ECF; Boothby CE; Griffin SJ
Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
